Systematic Analysis of Cell-of-Origin, Sequencing and Genomic Imbalances Identifies a Distinct Subset of Rituximab Treated Diffuse Large B-Cell Lymphoma with an Inferior Survival
Rajan Dewar(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Phillip Michaels(Brigham and Women's Hospital), Julia Friedman(Cancer Genetics (United States)), Sitharthan Kamalakaran(Columbia University Irving Medical Center), Daniel Xia(Beth Israel Deaconess Medical Center), Timothy George Lens(Beth Israel Deaconess Medical Center), Jane Houldsworth(Icahn School of Medicine at Mount Sinai), Asha Guttapalli(Cancer Genetics (United States)), Venkata J. Thodima(Cancer Genetics (United States))
Cited by 0
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals
|The American Journal of Human Genetics|2019|310
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
|Journal of Immunotherapy|2011|285